Rapid molecular detection of Zika Virus in acute-phase urine samples using the recombinase polymerase amplification assay
The development of a recombinase polymerase amplification assay is a promising platform for rapid point of need detection of ZIKV in low resource settings and elsewhere (e.g. during mass gathering).
A rapid point-of-care test is needed to detect zika virus, especially at low resource settings. A recombinase polymerase amplification assay was developed for zika virus DNA in urine samples. The clinical performance of the assay was evaluated on 25 acute-phase (2-10 days of onset of symptoms) urine samples collected from suspected cases at the Municipal Hospital of Tuparetama, Pernambuco, Brazil. All results were compared with a real-time RT-PCR as gold standard. The limit of the detection of the assay was 21 RNA copies/reaction. The RT-RPA identified 23/25 (Sensitivity: 92%) positive and 9/9 (specificity: 100%) negative samples.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.